Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVALT12: paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in metastatic non-squamous NSCLC
NL-OMON36516Phase 2Active, not recruiting
- Sponsor
- NVALT
- Start
- Jan 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nitroglycerin, bevacizumab, paclitaxel and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by NVALT. Primary endpoint: Progression-free survival. Started Jan 2011; status: active, not recruiting.
02
Drugs
nitroglycerinbevacizumabpaclitaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON36516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36516.